[SMMT]

The core of this positive news is AstraZeneca and Daiichi Sankyo's partnership with Summit for cancer clinical trials. Since the moving averages are not aligned and the market is in a bearish phase, cut losses if the 20-day support level of $15.18 is broken, and conversely, take profits if the upward trend continues and reaches the resistance level of $19.09. The current price of $16.69 is situated between the 20-day support line ($15.18) and resistance line ($19.09). As moving averages are unaligned in a bearish phase, a phased approach near the support line is deemed advantageous, leading to the consideration of a purchase. At the entry point, the technical indicators are confirmed as follows: RSI (14) at 43.9, moving averages out of alignment (non-bullish arrangement), trading volume at 1.03 times the 20-day average, and a -2.5% volatility rate over the past 7 days. We entered the position expecting a rebound near the 20-day support level ($15.18), backed by the heavy positive catalyst of AstraZeneca and Daiichi Sankyo's cancer clinical partnership. However, the actual outcome resulted in a -12.3% loss, earning a FAILED rating. The miscalculation stemmed from relying solely on the potential impact of the news, overlooking the bearish context at entry—namely, an RSI (14) of 43.9 and a non-aligned moving average structure—alongside a lack of meaningful volume explosion (1.03x the 20-day average) and ongoing downward pressure reflected in a -2.5% stock price change over the preceding 7 days. Through this failed trade, we confirmed that no matter how significant the partnership catalysts are in major pharmaceutical and biotech themes (such as AstraZeneca-related news), downward pressure can outweigh support in a bearish phase where moving averages have not yet formed a bullish alignment, provided support levels fail to hold firmly. Going forward, we will exercise utmost diligence in risk management by strictly evaluating not only macro indicators such as theme news trends and the S-Class conversion rate (15.9%), but also non-bullish alignments on technical indicators and the inflow of trading volume. Among past successful cases, the SMMT case, which recorded a 28.2% return on 2026-09-04, is similar to the current partnership news flow in that the keyword "AstraZeneca" overlaps. Other cases, VEEE (451.7%) and LRCX (346.8%), have no basis for direct similarity but are included for reference as top-performing cases globally.

The report states that Summit's key new drug, which serves as Akeso's lead drug, outperformed Astra's Imfinzi in a late-stage clinical trial. If the stock price reaches the resistance level of 15.75, take profits at $15.75; if it falls below the support level of 12.07, cut losses at $12.07. As the current price is $13.36, a rebound near the support level is expected. The current price of $13.36 is positioned between 12.07 (support) and 15.75 (resistance). Given its proximity to the support level and the potential for a rebound, a buy decision is being considered. RSI(14) 48.7 (neutral), moving averages not in bullish alignment (trend not established), trading volume at 1.28x the 20-day average (rising volume), 7-day price change +0.1% (almost no price movement). Compared to the predicted return of 2.5%, the actual return came in at 28.2%, resulting in an OVERHIT outcome. The entry decision based on news and support/resistance levels was accurate, but the gap stemmed from a significant underestimation of the magnitude of the rally. In the next trade, the same catalyst effect and price range will be utilized, while the target return will be adjusted upward to a more realistic level, and the position size will be increased if upward momentum is strong. In addition, trading volume surges and RSI changes will be monitored more closely to optimize the entry timing. The SMMT (2026-09-04) case, which overlapped on the same ticker, the same news, and the keyword 'ivonescimab', recorded a 28.2% return and shares the same catalyst and price range as the current trade. Although the VEEE (2026-07-16) and LRCX (2026-07-06) cases show no direct similarity, their high returns of 451.7% and 346.8%, respectively, can be referenced as an indication of the potential for high returns.